Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer

Breast disease Pub Date : 2023-12-22 DOI:10.3233/bd-230001

Solmaz Goldoost, H. Zarredar, M. Asadi, Milad Shirvaliloo, M. Raeisi

{"title":"Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer","authors":"Solmaz Goldoost, H. Zarredar, M. Asadi, Milad Shirvaliloo, M. Raeisi","doi":"10.3233/bd-230001","DOIUrl":null,"url":null,"abstract":"AIM: In the present study, we sought to explore potential differences in the expression and promoter methylation of mitogen-activated protein kinase 1 (MAPK1) between tumor and marginal cells of breast cancer lesions. METHODS: A total of 50 randomly selected patients with breast cancer (BCa) undergoing needle biopsy were enrolled. Clinical specimens containing both tumor and marginal cells were collected and preserved. After DNA extraction using specific primers, MAPK1 mRNA and promoter methylation were measured with spectrophotometry at 260/280 nm absorption wavelengths. To deliver a comparative analysis, data from The Cancer Genome Atlas (TCGA) program regarding breast cancer (BRCA), were downloaded from Xena Functional Genomics Explorer and separately analyzed. The suitability of MAPK1 expression and promoter methylation as biomarkers for BCa was analyzed with receiver operating characteristic (ROC) curves. RESULTS: We found a positive correlation between tumor stage and MAPK1 expression (P-value: 0.029) in BCa. Likewise, MAPK1 expression was significantly associated with lymph node metastasis (P-value: 0.018). There was a significant difference in the expression of MAPK1 mRNA between tumor and marginal cells of BCa and BRCA (P-value < 0.001). However, we did not find any statistically significant difference in MAPK1 promoter methylation between tumor and marginal cells of both BCa and BRCA. With an area under the curve (AUC) of 0.71, the diagnostic accuracy of MAPK1 expression in BCa and BRCA was validated. However, MAPK1 promoter methylation was not found to be a suitable biomarker. CONCLUSION: Our findings suggest that while MAPK1 expression, might be a promising biomarker for evaluating oncogenic activity in patients suspected of BCa. We were not able to detect a prognostic/diagnostic role for MAPK1 promoter methylation.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/bd-230001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

AIM: In the present study, we sought to explore potential differences in the expression and promoter methylation of mitogen-activated protein kinase 1 (MAPK1) between tumor and marginal cells of breast cancer lesions. METHODS: A total of 50 randomly selected patients with breast cancer (BCa) undergoing needle biopsy were enrolled. Clinical specimens containing both tumor and marginal cells were collected and preserved. After DNA extraction using specific primers, MAPK1 mRNA and promoter methylation were measured with spectrophotometry at 260/280 nm absorption wavelengths. To deliver a comparative analysis, data from The Cancer Genome Atlas (TCGA) program regarding breast cancer (BRCA), were downloaded from Xena Functional Genomics Explorer and separately analyzed. The suitability of MAPK1 expression and promoter methylation as biomarkers for BCa was analyzed with receiver operating characteristic (ROC) curves. RESULTS: We found a positive correlation between tumor stage and MAPK1 expression (P-value: 0.029) in BCa. Likewise, MAPK1 expression was significantly associated with lymph node metastasis (P-value: 0.018). There was a significant difference in the expression of MAPK1 mRNA between tumor and marginal cells of BCa and BRCA (P-value < 0.001). However, we did not find any statistically significant difference in MAPK1 promoter methylation between tumor and marginal cells of both BCa and BRCA. With an area under the curve (AUC) of 0.71, the diagnostic accuracy of MAPK1 expression in BCa and BRCA was validated. However, MAPK1 promoter methylation was not found to be a suitable biomarker. CONCLUSION: Our findings suggest that while MAPK1 expression, might be a promising biomarker for evaluating oncogenic activity in patients suspected of BCa. We were not able to detect a prognostic/diagnostic role for MAPK1 promoter methylation.

查看原文本刊更多论文

乳腺癌肿瘤细胞和边缘细胞中丝裂原活化蛋白激酶 1 的表达和启动子甲基化情况

目的：在本研究中，我们试图探讨乳腺癌病灶的肿瘤细胞和边缘细胞在丝裂原活化蛋白激酶 1 (MAPK1) 的表达和启动子甲基化方面的潜在差异。方法：我们随机选取了 50 名接受针刺活检的乳腺癌（BCa）患者。收集并保存含有肿瘤细胞和边缘细胞的临床标本。使用特定引物提取 DNA 后，用分光光度法在 260/280 纳米吸收波长下测量 MAPK1 mRNA 和启动子甲基化。为了进行比较分析，还从 Xena Functional Genomics Explorer 中下载了癌症基因组图谱（TCGA）计划中有关乳腺癌（BRCA）的数据，并分别进行了分析。用接收者操作特征曲线（ROC）分析了 MAPK1 表达和启动子甲基化作为 BCa 生物标志物的适宜性。结果：我们发现在 BCa 中，肿瘤分期与 MAPK1 表达呈正相关（P 值：0.029）。同样，MAPK1的表达与淋巴结转移也显著相关（P值：0.018）。BCa 和 BRCA 的肿瘤细胞和边缘细胞的 MAPK1 mRNA 表达存在明显差异（P 值<0.001）。然而，我们没有发现 BCa 和 BRCA 的肿瘤细胞和边缘细胞的 MAPK1 启动子甲基化有任何统计学上的显著差异。曲线下面积（AUC）为 0.71，验证了 MAPK1 在 BCa 和 BRCA 中表达的诊断准确性。然而，MAPK1 启动子甲基化并不是一个合适的生物标记物。结论：我们的研究结果表明，MAPK1表达可能是评估疑似BCa患者致癌活性的一种有前途的生物标志物。我们未能发现 MAPK1 启动子甲基化在预后/诊断方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.